ANZAN 2023 Novartis Posters
Characterizing the use of ofatumumab in a real-world setting (EAFToS): Secondary Use of Data Study characterizing ofatumumab onboarding and utilization in relapsing multiple sclerosis patients using MSGo
Anneke Van Der Walt, Todd Hardy, Simon Broadley, Jason Burton, Morag Nelson, Patricia Berry, Kate Martel, Rob Walker, Rozhin Asghari,
Leonie Bates
Novel Generation of Real-World Evidence through MSGo, a Digital Support Program Supporting the Use of Siponimod in Secondary Progressive Multiple Sclerosis Patients in Australia
Todd Hardy, Patrick Aouad, Michael Barnett, Stefan Blum, Simon Broadley, William Carroll, Denis Crimmins, Dayna Griffiths, Suzanne Hodgkinson, Jeannette Lechner-Scott, Andrew Lee, Ram Malhotra, Pamela McCombe, John Parratt, Chris Plummer, Anneke van der Walt, Kate Martel and Rob Walker
Cognitive Processing Speed Predicts Disability Milestones in Multiple Sclerosis
Danielle Howard, Hrishikesh Lokhande, Brian Healy, Virginia De Las Heras Revilla, Sophie Arnould, Bonnie Glanz, Jonathan Zurawski, Mariann Polgar-Turcsanyi, Taylor Saraceno, Howard Weiner, Tanuja Chitnis, Gina Drake
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Medical Information Service
Medical Enquires, Information services, Adverse Events and Product Complaints please contact:
Telephone: 1800 671 203
Mail: [email protected]
Colleagues are available from 9:00 to 17:00 from Monday to Friday
Please review Product Information before prescribing available at www.novartis.com/au-en/products/healthcare-professionals.
For medical enquiries please contact 1800 671 203.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/safety/reporting-problems.
For Ofatumumab prescribing information, please click here.
For Ofatumumab PBS status, please click here.
For Siponimod prescribing information, please click here.
For Siponimod PBS status, please click here.